Journal d'immunologie clinique et cellulaire
Libre accès
ISSN: 2155-9899
ISSN: 2155-9899
Qing Chen, Wang Liu, Zhongbin Zhoa*
Immunotherapy has revolutionized the treatment landscape for metastatic melanoma. This case report presents the clinical course of a patient with metastatic melanoma who received combination therapy with ipilimumab, a CTLA-4 checkpoint inhibitor, and an Indoleamine 2,3-Dioxygenase (IDO)-silenced Dendritic Cell (DC) vaccine. The treatment approach aimed to enhance antitumour immunity by blocking immune checkpoints and activating dendritic cells. The patient demonstrated a significant clinical response, indicating the diversification and potentiation of the antitumour effects. This case underscores the potential of combined immunotherapeutic strategies in achieving durable and robust antitumour effects.